The innovation highlights Akums continued focus on enhancing drug delivery systems and supporting key health needs with scientifically backed solutions. Given that up to 80% of pregnant women experience some form of nausea or vomiting, this dual-action tablet could significantly improve pregnancy nausea treatment

By simplifying dosing and prolonging relief, the tablet aligns with Akums’ broader mission to elevate standards in pharmaceutical manufacturing and patient-centric care. Akums Drugs & Pharmaceuticals, a prominent pharmaceutical contract manufacturer of India, has been awarded a patent for a pioneering extended-release tablet to address nausea and vomiting in pregnancy (NVP). The breakthrough carries the added distinction of DCGI approval, a major milestone in maternal care.

The new patented formulation integrates Doxylamine and Pyridoxine in a novel "tablet-in-tablet" format, providing immediate and prolonged relief in a single dose. The outer portion quickly dissolves to provide immediate symptom relief, with the inner core providing extended drug release over time—ultimately minimizing the requirement for several daily doses.

The bioequivalence study submitted to the regulatory approval met all parameters required, the company says, though certain results have not been revealed.

Earlier this month, the Drug Controller General of India (DCGI) approved the formulation, noting the tablet as a safer and more effective alternative for pregnant women with morning sickness and associated symptoms.

Given that up to 80% of pregnant women experience some form of nausea or vomiting, this dual-action tablet could significantly improve comfort and compliance.

(Input from various sources)

(Rehash/Sakshi Thakar/MSM)

MedBound Hub (https://www.medboundhub.com) is an emerging DISCUSSION FORUM for medical students and the healthcare professionals. Join this exciting healthcare forum.